Media stories about Cerecor (NASDAQ:CERC) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research firm rates the sentiment of media coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cerecor earned a news sentiment score of 0.02 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.7195823576307 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Shares of Cerecor (NASDAQ:CERC) opened at $5.26 on Tuesday. The company has a market cap of $136.26, a price-to-earnings ratio of 526.53 and a beta of 1.08. Cerecor has a twelve month low of $0.34 and a twelve month high of $5.74.
Separately, ValuEngine upgraded shares of Cerecor from a “sell” rating to a “hold” rating in a report on Friday, December 1st.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive Media Coverage Somewhat Unlikely to Affect Cerecor (CERC) Stock Price” was published by Stock Observer and is owned by of Stock Observer. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.thestockobserver.com/2018/03/20/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-cerecor-cerc-stock-price.html.
Cerecor Company Profile
Cerecor, Inc is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications, including CERC-301, which is an adjunctive treatment for major depressive disorder (MDD); CERC-501, which is for substance use disorders and adjunctive treatment of MDD, and CERC-406, which is for the treatment of cognitive impairment.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.